PatientsVille.com Logo

Glycogen storage disease type ii and Mozyme

PatientsVille

Glycogen Storage Disease Type Ii Symptoms and Causes

Metabolism is the process your body uses to make energy from the food you eat. Food is made up of proteins, carbohydrates, and fats. Chemicals in your digestive system (enzymes) break the food parts down into sugars and acids, your body's fuel. Your body can use this fuel right away, or it can store the energy in your body tissues. If you have a metabolic disorder, something goes wrong with this process.

Carbohydrate metabolism disorders are a group of metabolic disorders. Normally your enzymes break carbohydrates down into glucose (a type of sugar). If you have one of these disorders, you may not have enough enzymes to break down the carbohydrates. Or the enzymes may not work properly. This causes a harmful amount of sugar to build up in your body. That can lead to health problems, some of which can be serious. Some of the disorders are fatal.

These disorders are inherited. Newborn babies get screened for many of them, using blood tests. If there is a family history of one of these disorders, parents can get genetic testing to see whether they carry the gene. Other genetic tests can tell whether the fetus has the disorder or carries the gene for the disorder.

Treatments may include special diets, supplements, and medicines. Some babies may also need additional treatments, if there are complications. For some disorders, there is no cure, but treatments may help with symptoms.

Check out the latest treatments for glycogen storage disease type ii

glycogen storage disease type ii treatment research studies

Mozyme clinical trials, surveys and public health registries


Find Drug Side Effect reports



Mozyme Side Effects

Sepsis (3)
Respiratory Failure (1)
No Therapeutic Response (1)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Recent Reviews

A flu epidemic at a boarding school would be a concern for the Centers for Disease Control true or false?

Why do doctors keep the availabilty of the test for DPD deficiency a secret??? My sister is a doctor, infectious disease, at St Francis in Charleston, SC. Our father was treated by an oncologist well known to my sister, a 'colleague' you might s

Hi! am looking Operational and Installation manual for this type of x-ray machine Summit AmeriComp control console, with power module SHF 310 and other accessories of it. Well! let me give you this control console picture may be you will aware of

I am having cramps, muscle pain, memory loss, I have been on Revlmid for about 1 year. Does anybody else my age have this disease, I am only 46 yr woman.

I WANT FRIENDS WHO HAVE TYPE 1DIABETIC

sorry type errors if i could do it over i would have never taken this drug if i had only know .. wahtever you do don't just trust your doctor is doing the right thing or even a good thing for you like i did do

<b><span style=' padding: 0px; margin: 0px;'>Hi Can any1 tell me why this medicine (Betaserc) people use and if the disease is dangerous....plz tell me on urgent basis...any1 thnx</b>

My grand father was diagnosed with dementiaalzheimer's type and was prescribed Aricept. After he started taking Aricept, his condition have gotten worse and he actually died yesterday. He was 83 years old.

<span style='color: #808080;'><b>Describe Your Henoch-Schonlein purpura from INFLUENZA (H1N1) (H1N1 (MONOVALENT) SANOFI) 2010 Experience Here:</b> Vicious headaches, rash on legs and trunk, transient, cystitis type fee

<strong>I have very high blood pressure, was put on this drug approximately 5 weeks ago. I was on Coozar previous to this. I also take paracetamol x 1 bd, ceres x 1, venlafaxine x 1, omeprazole x 1, aspirin x 1, have Charcot Marie Tooth Disease

Glycogen Storage Disease Type Ii Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Not yet recruiting Pulmozyme in Cystic Fibrosis With Sinusitis
Conditions: Sinusitis;   Cystic Fibrosis
Interventions: Drug: Pulmozyme single use ampule;   Drug: placebo
Outcome Measure: 1. To assess changes in quality of life of patients with Cystic Fibrosis while on DNASE as compared to placebo.
2 Recruiting Dornase Alfa Therapy for Ventilator Associated Lung Infections in the Neonatal Intensive Care Unit (NICU)
Condition: Pulmonary Infections
Interventions: Drug: Dornase alfa;   Drug: Sham therapy
Outcome Measures: Percent Reduction in Oxygen Requirement from baseline;   Reduction in White Blood Cell count and Bacterial load from Tracheal Aspirate;   Number of days on Ventilator Support
3 Unknown  RhDNase and Biodistribution of PMN Serine Proteases in Cystic Fibrosis Sputum
Condition: Cystic Fibrosis
Intervention: Drug: Pulmozyme
Outcome Measure: The biodistribution of elastase, Protease 3 and cathepsine G in the expectorations will be measured by the management report of these proteases between the freezing fractionand the soluble fraction, before and after rhDNase administration.
4 Recruiting Preliminary Study of Dornase Alpha to Treat Chest Infections Post Lung Transplant.
Conditions: Lung Transplant Infection;   Lower Respiratory Tract Infection.
Interventions: Drug: Dornase Alpha;   Drug: Isotonic Saline.
Outcome Measures: Lung clearance index (LCI) - change;   Regular spirometry (FEV-1, FVC, FEF) - change;   Leicester Cough Questionnaire (LCQ) - change;   St. George's Respiratory Questionnaire (SGRQ) - change;   Inpatient days;   Oral, inhaled or IVAB days (for LRTI only).;   Number of hospitalizations;   Exacerbation rate.;   C-reactive protein (CRP) - change;   Breathlessness, Cough and Sputum Scale (BCSS) - change;   BronkoTest (sputum colour) - change
5 Unknown  Dornase Alfa and Urokinase for Kids With Pleural Empyema
Condition: Pleural Empyema
Interventions: Drug: Urokinase and Dornase alfa;   Drug: Urokinase
Outcome Measures: Duration of hospital stay;   Need for additional surgical procedures;   Duration of suction applied to chest drain;   Duration of fever;   Duration of intravenous antibiotic treatment
6 Not yet recruiting Combination Tissue Plasminogen Activator (Tpa) and Dornase Alfa (Dnase) Administration Through Intrapleural Catheters for the Treatment of Loculated or Non-Draining Malignant Pleural Effusions
Condition: Loculated or Non-draining Malignant Pleural Effusions
Intervention: Drug: Combination TISSUE PLASMINOGEN ACTIVATOR (TPA) AND DORNASE ALFA (DNASE)
Outcome Measure: Radiographic improvement in area of pleural collection
7 Recruiting Intrapleural DNase and Tissue Plasminogen Activator in Pediatric Empyema (DTPA Trial)
Condition: Pleural Empyema
Interventions: Drug: tPA;   Drug: DNase;   Other: Placebo
Outcome Measures: Time to hospital discharge;   Time to meeting discharge criteria;   Time to drain removal;   Duration of fever after intervention;   Need for ventilatory support or non-invasive ventilation following the intervention;   Serious bleeding;   Need for further interventions;   Hospital readmission;   Cost of the hospitalization;   Mortality